Skip to main content
NCBI home page
Clinical Cardiology logoLink to Clinical Cardiology
. 2006 Dec 5;27(2):63–69. doi: 10.1002/clc.4960270203

Patients with uncontrolled hypertension or concomitant hypertension and benign prostatic hyperplasia

Randall Zusman 1
PMCID: PMC6654573  PMID: 14979621

Abstract

At optimal doses, individual antihypertensive agents lower blood pressure (BP) by an average of 10 mmHg. Many patients with hypertension, including those with stage 3 hypertension, target organ damage, or those at high risk for cardiovascular events and/or adverse effects of high‐dose monotherapy, are likely to require combination antihypertensive drug treatment to achieve the recommended systolic/diastolic BP (< 140/90 mmHg). Two studies, a placebo‐controlled, double‐blind trial (n = 70) and a community‐based, open‐label trial (n = 491) investigated the antihypertensive efficacy of doxazosin, a long‐acting selective α1‐adrenoceptor blocker, as add‐on therapy for uncontrolled hypertension with other antihypertensive medications and in patients with concomitant benign prostatic hyperplasia (BPH) and treated but inadequately controlled hypertension, respectively. The addition of doxazosin to baseline antihypertensive medication(s) significantly lowered BP and had a significantly positive effect on the serum lipid profile. In patients with concomitant BPH, doxazosin significantly improved all BPH symptom scores, regardless of initial symptom severity. Add‐on doxazosin sufficiently reduced systolic/diastolic BP such that many patients whose hypertension was previously uncontrolled by other antihypertensive medications were able to reach goal BP (< 140/90 mmHg). Doxazosin as add‐on therapy was well tolerated. In conclusion, doxazosin as add‐on therapy improves BP control in hypertensive patients not at goal BP and improves lower urinary tract symptoms in patients with concomitant BPH.

Keywords: hypertension, doxazosin, benign prostatic, hyperplasia

Full Text

The Full Text of this article is available as a PDF (69.9 KB).

References

  • 1. The sixth report of the Joint National Committee (JNC‐VI) On prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 1997; 157: 2413–2446 [DOI] [PubMed] [Google Scholar]
  • 2. Weber MA, Radensky P: Measurement of short‐term, intermediate, and long‐term outcomes of treating hypertension. Cardiol Clin 1996; 14: 131–142 [DOI] [PubMed] [Google Scholar]
  • 3. National High Blood Pressure Education Program Working Group Report on primary prevention of hypertension. Arch Intern Med 1993; 153: 186–208 [PubMed] [Google Scholar]
  • 4. Hansson L: The Hypertension Optimal Treatment study and the importance of lowering blood pressure. J Hypertens 1999; (suppl) 17: S9–S13 [PubMed] [Google Scholar]
  • 5. Leslie RD: United Kingdom prospective diabetes study (UKPDS): What now or so what? Diabetes Metab Res Rev 1999; 15: 65–71 [DOI] [PubMed] [Google Scholar]
  • 6. Mogensen CE: Combined high blood pressure and glucose in type 2 diabetes: Double jeopardy. British trial shows clear effects of treatment, especially blood pressure reduction (editorial). Br Med J 1998; 317: 693–694 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7. Scheen AJ, Lefebvre PJ: Lessons from the “United Kingdom Prospective Diabetes Study.” Rev Med Liege 1998; 53: 576–578 [PubMed] [Google Scholar]
  • 8. MacConnachie A, Maclean D: Low dose combination antihypertensive therapy. Additional efficacy without additional adverse effects? Drug Saf 1995; 12: 85–90 [DOI] [PubMed] [Google Scholar]
  • 9. Dickerson JE, Hingorani AD, Ashby MJ, Palmer CR, Brown MJ: Optimisation of antihypertensive treatment by crossover rotation of four major classes. Lancet 1999; 353: 2008–2013 [DOI] [PubMed] [Google Scholar]
  • 10. Van Hoogdalem P, Donker AJ, Leenen F: Angiotensin II Blockade before and after marked sodium depletion in patients with hypertension. Clin Sci Mol Med 1978; 54: 75–83 [DOI] [PubMed] [Google Scholar]
  • 11. Coca A: Actual blood pressure control: Are we doing things right? J Hypertens 1998; (suppl) 16: S45–51 [PubMed] [Google Scholar]
  • 12. Caro JJ, Salas M, Speckman JL, Raggio G, Jackson JD: Persistence with treatment for hypertension in actual practice. CMAJ 1999; 160: 31–37 [PMC free article] [PubMed] [Google Scholar]
  • 13. Brown MJ, Dickerson JE: Synergism between alpha 1‐blockade and angiotensin converting enzyme inhibition in essential hypertension. J Hypertens 1991; (suppl) 9: S362–S363 [PubMed] [Google Scholar]
  • 14. Taylor S: Clinical pharmacotherapeutics of doxazosin. Am J Med 1989; 87: 2S–11S [DOI] [PubMed] [Google Scholar]
  • 15. Fulton B, Wagstaff A, Sorkin E: Doxazosin.: An update of its clinical pharmacology and therapeutic applications in hypertension and benign prostatic hyperplasia. Drugs 1995; 49: 295–320 [DOI] [PubMed] [Google Scholar]
  • 16. Grimm RJ Jr, Flack JM, Grandits GA, Elmer PJ, Neaton JD, Cutler JA, Lewis C, McDonald R, Schoenberger J, Stamler J, for the Treatment of Mild Hypertension Study (TOMHS) Research Group : Long‐term effects on plasma lipids of diet and drugs to treat hypertension. J Am Med Assoc 1996; 275: 1549–1556 [DOI] [PubMed] [Google Scholar]
  • 17. Fawzy A, Braun K, Lewis GP, Gaffney M, Ice K, Dias N: Doxazosin in the treatment of benign prostatic hyperplasia in normotensive patients: A multi‐center study. J Urol 1995; 154: 105–109 [PubMed] [Google Scholar]
  • 18. Gillenwater JY, Conn RL, Chrysant SG, Roy J, Gaffney M, Ice K, Dias N, for the Multicenter Study Group : Doxazosin for the treatment of benign prostatic hyperplasia in patients with mild to moderate essential hypertension: A double‐blind, placebo‐controlled, dose‐response multicenter study. J Urol 1995; 154: 110–115 [PubMed] [Google Scholar]
  • 19. Donnelly R, Elliott HL, Meredith PA, Howie CA, Reid JL: Combination of nifedipine and doxazosin in essential hypertension. J Cardiovasc Pharmacol 1992; 19: 479–486 [DOI] [PubMed] [Google Scholar]
  • 20. Lindner UK, von Manteuffel GE, Stafunsky M: The addition of doxazosin to the treatment regimen of hypertensive patients not responsive to nifedipine. Am Heart J 1988; 116: 1814–1820 [DOI] [PubMed] [Google Scholar]
  • 21. Brown M, Dickerson J: α‐Adrenoceptor blockade and Ca++ blockade: A new combination for the treatment of hypertension. J Hypertens 1991; 9 (suppl 6): 5362–5363 [Google Scholar]
  • 22. Englert RG, Barlage U: The addition of doxazosin to the treatment regimen of patients with hypertension not adequately controlled by beta‐blockers. Am Heart J 1991; 121: 311–316 [DOI] [PubMed] [Google Scholar]
  • 23. Searle M, Dathan R, Dean S, Christensen CC, Westheim A: Doxazosin in combination with atenolol in essential hypertension: A double‐blind placebo‐controlled multicentre trial. Eur J Clin Pharmacol 1990; 39: 299–300 [DOI] [PubMed] [Google Scholar]
  • 24. Stokes GS, Johnston HJ, Okoro EO, Boutagy J, Monaghan JC, Marwood JF: Comparative and combined efficacy of doxazosin and enalapril in hypertensive patients. Clin Exp Hypertens 1994; 16: 709–727 [DOI] [PubMed] [Google Scholar]
  • 25. Englert RG, Mauersberger H: A single‐blind study of doxazosin in the treatment of essential hypertension when added to nonresponders to angiotensin‐converting enzyme inhibitor therapy. Am Heart J 1988; 116: 1826–1832 [DOI] [PubMed] [Google Scholar]
  • 26. Troffa C, Manunta P, Sessi‐Fulgheri P, Pazzola A, Sabino G, Patteri G, Tonolo G, Pupita G, Glorioso N, Gitti M, Rappelli A: Efficacy and tolerability of doxazosin alone or in combination with chlorthalidone in essential hypertension. Curr Ther Res 1994; 55: 22–31 [Google Scholar]
  • 27. Marti‐Canales JC, Ceballos R, Puerta‐Jiminez LM, Gil‐Extremera B, Sanz‐Burgoa V: Comparative study of doxazosin and hydrochlorothiazide when added to nonresponders to ARBII losarthan therapy. Am J Hypertens 2001; 14 (4[suppl]): A177 [Google Scholar]
  • 28. Nalbantgil S, Nalbantgil I, Onder R: Clinically additive effect between doxazosin and amlodipine in the treatment of essential hypertension. Am J Hypertens 2000; 13: 921–926 [DOI] [PubMed] [Google Scholar]
  • 29. Hunter Hypertension Research Group : Combined effect of doxazosin and pindolol on blood pressure control and lipid concentrations in patients with essential hypertension selected from general practice. J Hum Hypertens 1992; 6: 181–184 [PubMed] [Google Scholar]
  • 30. Brown M, Dickerson J: Alpha‐blockade and calcium antagonism: An effective and well‐tolerated combination for the treatment of resistant hypertension. J Hypertens 1995; 13: 701–707 [DOI] [PubMed] [Google Scholar]
  • 31. Rachmani R, Levi Z, Slavachevsky I, Half‐Onn E, Ravid M: Effect of an alpha‐adrenergic blocker, and ACE inhibitor and hydrochlorothiazide on blood pressure and on renal function in type 2 diabetic patients with hypertension and albuminuria. A randomized cross‐over study. Nephron 1998; 80: 175–182 [DOI] [PubMed] [Google Scholar]
  • 32. Black HR, Sollins JS, Garofalo JL: The addition of doxazosin to the therapeutic regimen of hypertensive patients inadequately controlled with other antihypertensive medications: A randomized, placebo‐controlled study. Am J Hypertens 2000; 13: 468–474 [DOI] [PubMed] [Google Scholar]
  • 33. Guthrie RM, Siegel RL: A multicenter, community‐based study of doxazosin in the treatment of concomitant hypertension and symptomatic benign prostatic hyperplasia: The Hypertension and BPH Intervention Trial (HABIT). Clin Ther 1999; 21: 1732–1748 [DOI] [PubMed] [Google Scholar]
  • 34. Boyle P, Napalkov P: The epidemiology of benign prostatic hyperplasia and observations on concomitant hypertension. Scand J Urol Nephrol 1995; (suppl) 168: 7–12 [PubMed] [Google Scholar]
  • 35. Guthrie R: Terazosin in the treatment of hypertension and symptomatic benign prostatic hyperplasia: A primary care trial. J Fam Pract 1994; 39: 129–133 [PubMed] [Google Scholar]
  • 36. ALLHAT Collaborative Research Group: Major cardiovascular events in hypertensive patients randomized to doxazosin vs. chlorthalidone: The antihypertensive and lipid‐lowering treatment to prevent heart attack trial (ALLHAT). J Am Med Assoc 2000; 283 (15)1967–1975 [PubMed] [Google Scholar]
  • 37. The Antihypertensive and Lipid‐Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Collaborative Research Group : Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs. usual care: The Antihypertensive and Lipid‐Lowering Treatment to Prevent Heart Attack Trial (ALLHAT‐LLT). J Am Med Assoc 2002; 288 (23) 2998–3007 [DOI] [PubMed] [Google Scholar]

Articles from Clinical Cardiology are provided here courtesy of Wiley

RESOURCES